Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
Digital Pathology Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031..., Market Research Report: MarketsandMarkets
Дата публикации: 24-06-2026 00:00:00
Основное содержимое страницы с новостью.
Digital Pathology Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031
USD 1.58 BN
MARKET SIZE, 2026
USD 2.86 BN
MARKET SIZE, 2031
2026-2031
FORECAST PERIOD
DIGITAL PATHOLOGY MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global digital pathology market is projected to grow from USD 1.58 billion in 2026 to USD 2.86 billion by 2031, at a CAGR of 12.5% during the forecast period. The market was valued at USD 1.42 billion in 2025. Market is driven by rapid digital transformation across hospitals, increasing adoption of cloud-based solutions, rising cancer incidence and the growing demand for faster and more accurate disease diagnosis, increasingly utilizing digital pathology in drug discovery, preclinical research, and clinical trials, creating additional demand for digital imaging and analytical solutions.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Market Size (2025): USD 1.42 Billion
Market Size (2026): USD 1.58 Billion
Projected Market Size (2031): USD 2.86 Billion
CAGR (2026–2031): 12.5% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest market share of 40.1% in 2025.
Therapeutic Area Leader: Oncology held more than 55% of the market in 2025.
Fastest-Growing Type: Veterinary pathology is projected to register the highest CAGR of 14.4% during the forecast period.
Fastest-Growing Technology: AI-enabled digital pathology is projected to register the highest CAGR during the forecast period. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
The market is driven by rapid digital transformation across hospitals, increasing adoption of cloud-based solutions, rising cancer incidence, and growing demand for faster and more accurate disease diagnosis.
Leading companies include Danaher Corporation, F. Hoffmann-La Roche, and Koninklijke Philips N.V..
Emerging companies such as Motic Digital Pathology and Mikroscan Technologies, Inc. have established strong positions in specialized niche areas.
The digital pathology market is driven by the increasing adoption of teleconsultation services, growing applications in drug discovery, and rising demand for accurate diagnosis of chronic diseases such as cancer. Additionally, the expanding use of digital pathology by physicians and researchers in oncology, anatomical pathology, and preclinical toxicology is accelerating market growth by improving diagnostic efficiency and research outcomes.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The digital pathology market is undergoing a profound transformation, driven by a powerful combination of technological, clinical, and operational forces that are fundamentally changing the practice of pathology. Rising cancer incidence, growing demand for faster and more accurate diagnostics, and the increasing use of artificial intelligence and machine learning in pathology interpretation are core drivers, with digital pathology solutions enabling improved collaboration, remote case reviews, and enhanced diagnostic efficiency across healthcare systems globally.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The use of digital pathology will enable laboratories to operate more efficiently through decreased costs, reduced turnaround times, and increased convenience for pathologists in consulting other experts or getting an opinion on specific cases. Quick and efficient laboratory results are essential since healthcare practitioners and patients depend on them to guide treatment plans and diagnose illnesses. The review of digital slides eliminates the process of delivering physical slides to laboratories and saves both time and money spent on transport. Moreover, artificial intelligence increases the efficiency of digital pathology services by assisting pathologists in reviewing slides very fast compared to manual methods. Artificial intelligence is able to detect cases that demand urgent attention by pathologists and also help them with other routine tasks to enable them to attend to complicated cases.
The large amount of capital needed for the deployment of digital pathology continues to be one of the biggest challenges for market adoption, especially in smaller labs. To completely transform to a digital system, a lot of investment is needed into WSI scanners, image management software, AI applications, workflow software, networking infrastructure, and computer systems capable of performing such tasks. Depending on the scanning capacity and features of these systems, high-throughput digital pathology scanners may range in price from tens to hundreds of thousands of dollars, and additional costs are required for licensing fees, software installation services, validation tests, and employee training. This leads to laboratories adopting digital pathology gradually in order to keep the costs low and to see some benefits from their investment. The cost of a digital pathology system depends on such aspects as its degree of automation, imaging capacity, and other features. A new system might cost around USD 50,000 to USD 200,000, depending on the sophistication.
The cost factor associated with the scanners and other hardware in the digital pathology market is one of the main constraints faced by the market. Thus, there are possibilities of growth due to the development of cheap scanners within the market for digital pathology. Since most of the private clinics are small entities, they are unable to spend much on digital pathology equipment. The development of cheap scanners and small firms' interest in digital pathology will lead to their usage by pathologists with small budgets. The company DigiPath (US) manufactures affordable scanners. It provides scanners starting from USD 25,000. Mikroscan Technologies (US) is one of the leading manufacturers of whole slide imaging and offers an advanced personal desktop scanner called MikroScan D2.
In this regard, it is essential to consider the security and confidentiality of data in digital pathology, where high-resolution whole-slide images, along with clinical data, are transmitted, exchanged, and analyzed using digital technology. The size of the data can be up to several gigabytes, making it susceptible to attacks during transfer or storage. Given that digital pathology systems are integrated with cloud-based AI technologies as well as healthcare institutions' network systems, there are inherent risks of such cyberattacks. According to the 2025 Healthcare Data Breach Report, the number of data breaches in the healthcare industry comes to 700 per year, with each case affecting at least 500 patients, as reported to the US Department of Health & Human Services Office for Civil Rights. While the trend was similar in 2025 compared to the previous year, the number of incidents decreased. According to present statistics, there was an approximately 4.3% decrease in healthcare data breach cases in 2025. As per IBM's Cost of Data Breach report, the mean cost of a data breach in the healthcare industry came to USD 10.93 million in 2023.
DIGITAL PATHOLOGY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Digital pathology workflow solutions including slide digitization, pathology image management, and AI-assisted analysis for clinical diagnostics and life sciences research. | Faster case review, improved workflow efficiency, reduced manual workload, and enhanced diagnostic consistency. |
|
|
Integrated digital pathology and companion diagnostics platform supporting biomarker testing, oncology research, and precision medicine applications. | Improved biomarker assessment, faster treatment decisions, enhanced diagnostic accuracy, and support for personalized medicine. |
|
|
Whole-slide imaging, digital pathology management, and remote pathology solutions for hospitals, laboratories, and healthcare networks. | Reduced turnaround times, increased pathologist productivity, remote collaboration, and optimized laboratory operations. |
|
|
Enterprise digital pathology platform enabling storage, sharing, viewing, and management of pathology images across multiple sites. | Centralized image access, improved collaboration, secure data management, and streamlined pathology workflows. |
|
|
High-resolution whole-slide scanners and digital imaging systems for pathology laboratories, academic institutions, and pharmaceutical research. | Superior image quality, faster slide digitization, support for remote diagnostics, and increased laboratory throughput. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The digital pathology market ecosystem comprises industry leaders such as Danaher Corporation, F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., Sectra AB, and Hamamatsu Photonics, which contribute significantly to the market environment by providing products and services that include whole-slide scanners, software solutions for digital pathology, imaging management systems, and diagnostics tools based on artificial intelligence. Companies such as Mikroscan Technologies and Motic Digital Pathology are transforming the domain of computational pathology by applying advanced image analysis through artificial intelligence algorithms. Regulators, such as the Food and Drug Administration, as well as standard-setting organizations, play an important role in ensuring the highest level of product quality, patient safety, and compliance within the market. End users include hospitals, diagnostic centers, pharmaceutical organizations, biotech companies, and research institutions that use digital pathology for diagnosis, precision medicine, telepathology, and drug discovery programs.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Based on product, the hardware accounts for the largest share of the digital pathology market, which is mainly attributable to its importance in facilitating the digitalization of pathology. The digital pathology market consists of various hardware categories, where whole-slide imaging (WSI) scanners represent essential components that form the basis of the technology through the transformation of conventional glass slides into electronic images, which can then be reviewed, studied, saved, and shared. The rising popularity of digital pathology within hospitals, labs, universities, and research facilities has resulted in a greater need for more sophisticated scanning machines.
Based on the type, the digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share owing to the increasing occurrence of cancers and other chronic diseases that require a correct diagnosis. The increasing demand for precision medicines, a high number of pathology tests performed, and increased adoption of digital pathology technology in hospitals, diagnostic laboratories, and medical facilities are some of the key factors fueling the growth of the segment. Digital pathology not only facilitates faster slide reviews but also enhances diagnosis accuracy through consultations and cooperation between specialists. Moreover, the growing use of AI-based image analysis, increased healthcare investments in digitization, and the growing use of digital pathology in diagnosing diseases and devising treatment plans are some other reasons behind the dominance of the segment in the market.
Based on the therapeutic area, the digital pathology market may be divided into oncology, hematology, gastroenterology, infectious diseases, neurology, and other therapeutic areas. Of all these segments, the oncology segment is the one that accounts for the highest market share in the digital pathology market, and is the most important application segment for digital pathology technologies. This is chiefly due to the increasing incidence of cancer in different parts of the world and the growing need for rapid and accurate diagnostics of disease. The need for more personalized and accurate treatment of cancers is another factor that increases the usage of digital pathology in the oncology segment.
Based on technology, the digital pathology market is segmented into conventional digital pathology and AI-enabled digital pathology. In 2025, conventional digital pathology holds a significant share of the digital pathology market, driven by high adoption rates of WSI scanners, digital workflow management, and image management software in various healthcare facilities such as hospitals, diagnostic centers, and other research institutes. Most healthcare providers continue to emphasize digitization of their pathology departments through the conversion of existing microscopy techniques to digital slides that can be scanned, stored, viewed, and shared remotely. Increasing usage of WSI systems, increased telepathology requirements, growing numbers of pathology cases, and the necessity of operational efficiency further reinforce this trend.
Based on application, the digital pathology market is segmented into clinical diagnostics, pre-clinical research, clinical trials, telepathology, academic & translational research, education & training, and others. The clinical diagnostics segment is expected to hold for the significant share of the market in 2025, owing to the growing use of digital pathology for everyday disease diagnosis and cancer screening and for improving pathology procedures. Increasing caseloads at hospitals and labs, rising incidences of cancers, increasing need for efficient and faster diagnosis processes, and growing approvals of digital pathology systems are driving their use. In addition to these factors, the introduction of artificial intelligence, whole slide imaging technology, and image analysis techniques in clinical processes has increased diagnostic efficiency and enabled precision medicine programs.
Based on end users, the digital pathology market can be classified as hospitals & health systems, diagnostic & reference laboratories, veterinary laboratories, pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and others. The share of hospitals & health systems is expected to grow significantly during 2025 because of the extensive adoption of digital pathology products in making primary diagnoses, increasing workload, higher cancer cases, and investments made in digital transformation within the healthcare sector. Digital pathology solutions, including WSI scanners, imaging software, AI-enabled diagnostics, and telepathology, are being adopted by hospitals to boost operational productivity and provide accurate diagnoses. Moreover, the approvals secured by digital pathology solutions, the need for remote consultation, and advancements in precision.
REGION
Asia Pacific registered the highest CAGR during the forecast period (2026-2031) in the digital pathology market
Being home to almost two-thirds of the world’s population, the Asia Pacific’s health care requirements have changed, particularly for countries such as China, with ten million senior citizens added every year. Several actions from the governments have been taken: the Healthy China 2030 initiative of China, which intends to improve healthcare facilities. At the same time, Indian health care has increased more than 20% during the past five years due to increased government and private expenditures on health care services, along with advancements in health care equipment. Investment in health care in the APAC region has become one of the fastest-growing trends, with the main driver being Southeast Asia, owing to investments in infrastructural facilities and digitization. FDI investments in the healthcare sector in the post-COVID period are seeing a revival, with the United States being the major investor.
DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
Danaher Corporation (Star) occupies a leadership position through its subsidiary, Leica Biosystems, which offers a full range of products spanning tissue diagnosis, whole-slide imaging scanner systems, pathology workflow automation solutions, and digital pathology systems. The company has a good global reach, a wide installed base, and an innovative approach towards pathology imaging solutions. Healthcare institutions benefit from Danaher Corporation's strategic alliances and integrated pathology system in achieving greater digital transformation, faster and more efficient diagnostics, and better support for precision medicine programs. As for Indica Labs (Emerging Leader), the company enhances its market position through the development of image analysis and computational pathology systems. The HALO suite allows users to conduct digital pathology research, quantify biomarkers, perform companion diagnostics, and conduct image analysis using artificial intelligence. Indica Labs' growing customer base and further developments of technology will play an important role in the future growth and success of this emerging leader in the digital pathology landscape.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 1.42 Billion |
| Market Forecast in 2026 (Value) | USD 1.58 Billion |
| Market Forecast in 2031 (Value) | USD 2.86 Billion |
| Growth Rate | 12.5% form 2026-2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: DIGITAL PATHOLOGY MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Detailed Insights on Digital Pathology Products | Segmented analysis of scanners, software, and storage systems, including technology trends, adoption patterns, and market sizing. | Facilitated targeted investment decisions across high-growth product segments |
| Competitive Landscape Enhancement | Additional profiling of 15–20 regional digital pathology vendors and emerging startups | Improved vendor benchmarking and partnership strategy development |
| Regional Market Breakout | Country-level data for the US, Canada, Germany, UK, China, India, and Japan with growth drivers | Supported market-entry prioritization based on opportunity size and regulatory landscape |
| End-User Workload & Adoption Insights | Detailed analysis of adoption trends for pharmaceutical & biotechnology companies, hospitals & reference laboratories, academic & research institutes, diagnostic laboratories, and veterinary laboratories. | Strengthened go-to-market strategy with sharper understanding of buyer needs |
| Digital Pathology Workflow Assessment | Comprehensive analysis of slide digitization, image management, remote consultation, and pathology workflow optimization solutions. | Enabled identification of operational efficiency improvement opportunities for healthcare organizations. |
RECENT DEVELOPMENTS
- May 2026 : Hamamatsu Corporation collaborated with the Keck School of Medicine of USC to advance real-world digital pathology workflow optimization, including the deployment of multiple NanoZoomer slide scanning systems to support pathology workflow research and evaluation.
- April 2026 : Aiforia entered into an agreement with Laboratorio di Analisi La Fontana, a private diagnostic laboratory in Italy, to advance the use of AI in digital pathology. Through Aiforia’s AI development platform, Aiforia Create, the laboratory plans to develop deep learning-based AI models for the analysis of cervical cancer samples. These AI models are expected to be integrated into routine clinical workflows to improve diagnostic efficiency and accuracy, with future plans to expand the use of AI applications across additional areas of women's health.
- March 2026 : Philips expanded its digital pathology portfolio with the cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite, which helps pathology laboratories adopt and scale digital workflows without the complexity of on-premise infrastructure.
- January 2026 : Sectra AB collaborated with Kameda Medical Center. Sectra initiated its first digital pathology implementation in Japan with distribution partner Matsunami Glass, supporting enhanced cancer diagnostic workflows and helping reduce the time between diagnosis and treatment initiation.
- January 2024 : Roche received 510(k) clearance from the US FDA for its whole-slide imaging system, Ventana DP 200. This system aims to assist pathologists in recovering & interpreting digital images of scanned pathology slides for diagnostic purposes.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.4.2.1.1
AI-ENABLED DIGITAL PATHOLOGY IMPROVING LABORATORY THROUGHPUT, WORKFLOW EFFICIENCY, AND DIAGNOSTIC ACCURACY
4.2.1.2
RISING BURDEN OF CANCER AND OTHER CHRONIC DISEASES INCREASING PATHOLOGY TESTING VOLUMES
4.2.1.3
EXPANDING ADOPTION OF DIGITAL PATHOLOGY IN DRUG DISCOVERY, BIOMARKER VALIDATION, AND CLINICAL RESEARCH
4.2.1.4
GROWING ADOPTION OF COMPUTATIONAL PATHOLOGY AND ADVANCED IMAGE ANALYSIS TECHNOLOGIES
4.2.1.5
INCREASING SHORTAGE OF PATHOLOGISTS DRIVING LABORATORY DIGITIZATION AND WORKFLOW AUTOMATION
4.2.1.6
RISING ADOPTION OF TELEPATHOLOGY AND REMOTE DIAGNOSTIC WORKFLOWS
4.2.1.7
GROWING INTEGRATION OF DIGITAL PATHOLOGY WITH LIS, EHR, PACS, AND LABORATORY INFORMATION SYSTEMS
4.2.1.8
NATIONAL CANCER SCREENING PROGRAMS AND HEALTHCARE DIGITALIZATION INITIATIVES SUPPORTING DIGITAL PATHOLOGY ADOPTION
4.2.2.1
HIGH INITIAL CAPITAL INVESTMENT FOR SCANNERS, SOFTWARE PLATFORMS, AND STORAGE INFRASTRUCTURE
4.2.2.2
DATA INTEROPERABILITY ISSUES WITH LEGACY LABORATORY AND HEALTHCARE INFORMATION SYSTEMS
4.2.2.3
REGULATORY AND REIMBURSEMENT UNCERTAINTIES ACROSS KEY MARKETS
4.2.2.4
LARGE-SCALE IMAGE STORAGE, ARCHIVING, AND DATA MANAGEMENT REQUIREMENTS
4.2.2.5
LIMITED STANDARDIZATION ACROSS DIGITAL PATHOLOGY WORKFLOWS, IMAGE FORMATS, AND DEPLOYMENT PRACTICES
4.2.3.1
GROWING ADOPTION OF DIGITAL BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL RESEARCH
4.2.3.2
INCREASING UTILIZATION OF COMPANION DIAGNOSTICS AND PRECISION ONCOLOGY APPLICATIONS
4.2.3.3
GROWTH OF CLOUD-NATIVE DIGITAL PATHOLOGY PLATFORMS AND SAAS-BASED DEPLOYMENT MODELS
4.2.3.4
AFFORDABLE SCANNER DEVELOPMENT ENABLING ADOPTION IN LOW-RESOURCE SETTINGS
4.2.4.1
ALGORITHM VALIDATION, EXPLAINABILITY, AND CLINICAL TRUST IN AI-ASSISTED DIAGNOSTICS
4.2.4.2
DATA PRIVACY, CYBERSECURITY, AND PATIENT INFORMATION PROTECTION CONCERNS
4.2.4.3
INTEGRATION COMPLEXITY ACROSS HETEROGENEOUS HEALTHCARE IT ENVIRONMENTS
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Captures industry movement, adoption patterns, and strategic signals across key end-use segments and regions.5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMICS INDICATORS
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.5.1
INDICATIVE PRICING FOR DIGITAL PATHOLOGY MARKET, BY PRODUCT (2025)
5.5.2
INDICATIVE PRICING FOR DIGITAL PATHOLOGY MARKET, BY REGION (2025)
5.6.1
IMPORT SCENARIO (HS CODE 90118000)
5.6.2
EXPORT SCENARIO (HS CODE 90118000)
5.7
KEY CONFERENCES AND EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.11
IMPACT OF 2025 US TARIFF – DIGITAL PATHOLOGY MARKET
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
IMPACT ON COUNTRIES/REGIONS
5.11.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
CLOUD STORAGE & ARCHIVING
6.1.2
WHOLE SLIDE IMAGING (WSI) SCANNERS
6.1.3
IMAGE MANAGEMENT SYSTEMS
6.1.4
AI-ENABLED IMAGE ANALYSIS & COMPUTATIONAL PATHOLOGY PLATFORMS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
LIS, EHR & PACS INTEGRATION
6.2.2
DIGITAL BIOMARKER PLATFORMS
6.2.3
COMPANION DIAGNOSTIC PLATFORMS
6.2.4
TELEPATHOLOGY & REMOTE COLLABORATION PLATFORMS
6.3
ADJACENT TECHNOLOGIES
6.3.2
MULTI-OMICS PLATFORMS
6.3.3
PRECISION MEDICINE PLATFORMS
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON DIGITAL PATHOLOGY
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES FOLLOWED BY SOLUTION PROVIDERS IN DIGITAL PATHOLOGY
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN THE DIGITAL PATHOLOGY MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED DIGITAL PATHOLOGY PRODUCT
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
DIGITAL PATHOLOGY MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million9.2.1
WHOLE SLIDE IMAGING (WSI) SCANNERS
9.2.1.1
BRIGHTFIELD SCANNERS
9.2.1.2
FLUORESCENCE SCANNERS
9.2.2
WORKSTATIONS & VIEWING SYSTEMS
9.2.3
PERIPHERALS & ACCESSORIES
9.3.1
ENTERPRISE DIGITAL PATHOLOGY SOLUTIONS/PLATFORMS
9.3.2
IMAGE MANAGEMENT SOFTWARE
9.3.3
IMAGE ANALYSIS SOFTWARE
9.3.4
AI & COMPUTATIONAL PATHOLOGY SOFTWARE
10
DIGITAL PATHOLOGY MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million10.3
VETERINARY PATHOLOGY
11
DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million11.2
CONVENTIONAL DIGITAL PATHOLOGY
11.3
AI-ENABLED DIGITAL PATHOLOGY
12
DIGITAL PATHOLOGY MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million12.2
CLINICAL DIAGNOSTICS
12.3
PRE-CLINICAL RESEARCH
12.3.1
DRUG DISCOVERY & EFFICACY STUDIES
12.3.2
TOXICOLOGY & SAFETY ASSESSMENT
12.3.3
BIOMARKER DISCOVERY & VALIDATION
12.3.4
OTHER PRE-CLINICAL RESEARCH
12.6
ACADEMIC & TRANSLATIONAL RESEARCH
12.7
EDUCATION & TRAINING
12.8
OTHERS (FORENSIC PATHOLOGY, PUBLIC HEALTH PATHOLOGY, BIOBANKING APPLICATIONS, TOXICOLOGIC PATHOLOGY (NON-DRUG DEVELOPMENT, ETC.
13
DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million13.4
GASTROINTESTINAL DISEASE
13.7
OTHERS (DERMATOLOGY, RENAL DISEASE, HEPATIC DISEASE, ENDOCRINE & RARE DISEASE)
14
DIGITAL PATHOLOGY MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million14.2
HOSPITALS & HEALTH SYSTEMS
14.3
DIAGNOSTIC & REFERENCE LABORATORIES
14.4
VETERINARY LABORATORIES
14.5
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.6
CONTRACT RESEARCH ORGANIZATIONS (CROS)
14.7
ACADEMIC & RESEARCH INSTITUTES
14.8
OTHERS (GOVERNMENT LABORATORIES, PUBLIC HEALTH AGENCIES, MILITARY MEDICAL LABORATORIES, FORENSIC LABORATORIES, BIOBANKS AND TISSUE BANKS, ETC.)
15
DIGITAL PATHOLOGY MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031)
Market Size, Volume & Forecast – USD Million15.4.6
REST OF ASIA PACIFIC
15.5.3
REST OF LATIN AMERICA
15.6
MIDDLE EAST & AFRICA
15.6.3
REST OF MIDDLE EAST & AFRICA
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
16.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
16.3
REVENUE ANALYSIS (2021-2025)
16.4
MARKET SHARE ANALYSIS (2025
16.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
15.6.5.1
COMPANY FOOTPRINT
15.6.5.2
REGION FOOTPRINT
15.6.5.3
PRODUCT FOOTPRINT
15.6.5.4
APPLICATION FOOTPRINT
15.6.5.5
END USER FOOTPRINT
16.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
16.7.1
PROGRESSIVE COMPANIES
16.7.3
RESPONSIVE COMPANIES
16.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
16.8
COMPANY VALUATION AND FINANCIAL METRICS
16.9
COMPETITIVE SCENARIOS
16.9.1
PRODUCT LAUNCHES & UPGRADES
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE DIGITAL PATHOLOGY MARKET LANDSCAPE
17.1.1
DANAHER CORPORATION
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.1.3.2
STRATEGIC CHOICES
17.1.1.3.3
WEAKNESS/COMPETITIVE THREATS
17.1.2
F. HOFFMANN-LA ROCHE LTD
17.1.3
KONINKLIJKE PHILIPS N.V.
17.1.5
HAMAMATSU PHOTONICS
17.1.7
FUJIFILM HOLDINGS CORPORATION
17.1.10
APOLLO ENTERPRISE IMAGING CORP.
17.1.11
HURON TECHNOLOGIES INTERNATIONAL INC.
17.1.14
GLENCOE SOFTWARE, INC
17.2.2
KONFOONG BIOTECH INTERNATIONAL CO., LTD.
17.2.3
MIKROSCAN TECHNOLOGIES, INC
17.2.4
MOTIC DIGITAL PATHOLOGY
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.1.2
LIST OF KEY SECONDARY SOURCES
18.1.2.1
KEY DATA FROM PRIMARY SOURCES
18.1.2.2
KEY PRIMARY PARTICIPANTS
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
KEY INDUSTRY INSIGHTS
18.2
MARKET SIZE ESTIMATION
18.2.1
BOTTOM-UP APPROACH
18.2.3
MARKET SIZE CALCULATION FOR BASE YEAR
18.3
MARKET FORECAST APPROACH
18.6
RESEARCH ASSUMPTIONS AND LIMITATIONS
19.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
Methodology
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the digital pathology market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the digital pathology market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, hospitals, diagnostic laboratories, and academic & research institutes.
*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = > USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the digital pathology market was determined through data triangulation using the two approaches described below. After completing each approach, a weighted average was calculated based on the level of assumptions used in each approach.
Data Triangulation
The size of the digital pathology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the digital pathology market were gathered from secondary sources to the extent available. In certain cases, shares of digital pathology businesses have been determined through a detailed analysis of various parameters, including product portfolios, market positioning, selling prices, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the digital pathology market was determined by extrapolating the market share data of major companies.
Market Definition
Digital pathology is an image-based information environment for managing and interpreting information generated from digitized glass slides. The process involves converting glass slides to digital pathology slides using digital pathology scanning solutions. A digital image is then generated, enabling high-resolution slide viewing.
Key Stakeholders
- Healthcare Institutions/Providers (Hospitals, Medical Groups, Physician Practices, Diagnostic Centers, Ambulatory Centers, and Outpatient Clinics)
- Digital Pathology Organizations
- Senior Management
- Finance/Procurement Department
- R&D Department
- Healthcare Data Aggregators
- Venture Capitalists
- Government Agencies
- Healthcare Startups, Consultants, and Regulators
- Academic Medical Institutes
Report Objectives
- To define, describe, and forecast the digital pathology market based on product, type, technology, application, therapeutic area, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall digital pathology market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa.
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall digital pathology market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific digital pathology market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe digital pathology market into Russia, Austria, Finland, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Frequently Asked Questions (FAQ)
Prominent players include Fujifilm Holdings Corporation (Japan), Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Mikroscan Technologies, Inc. (US), PathAI (US), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Proscia Inc. (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Motic Digital Pathology (US), and Kanteron Systems (Spain).
Human Pathology and Veterinary Pathology.
North America is expected to hold the largest market share. The Asia Pacific region is projected to register the highest growth during the forecast period.
Pharmaceutical & Biotechnology Companies, Hospitals, Diagnostic Labs, and Academic & Research Institutes.
The market is expected to record a CAGR of 13.5% from 2025 to 2030.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Digital Pathology Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Схожие новости
Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 5. Источник: www.marketsandmarkets.com.